RxDoctor Payments Data

Anette McGowan

Neuroscience · Rancho Mirage, CANPI 1962478479

Payments from drug & device makers

$28,354in general payments, 2019–2025

Across 1,082 payments — averaging $26.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$2K
  • AstraZeneca$2K
  • Pfizer$1K
  • Incyte Corporation$1K
  • GSK$1K
  • plus $18K from 54 others

What the payments were for

  • Food & beverage$26,10392%
  • Education$7203%
  • Other$1,5315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis117$3,297
Johnson & Johnson61$1,598
AstraZeneca(2 entities)48$1,586
Pfizer57$1,270
Incyte Corporation39$1,132
GSK39$1,058
Merck48$1,048
Gilead(2 entities)29$1,041
Seagen Inc.32$847
Daiichi Sankyo Inc.33$836
Sobi, Inc18$829
AbbVie23$726
Amgen25$703
Eisai Inc.23$674
Sanofi24$660
Takeda Pharmaceuticals U.S.A., Inc.24$606
Regeneron Healthcare Solutions, Inc.26$549
Beigene USA, Inc.17$540
E.r. Squibb & Sons, L.L.C.30$482
Blueprint Medicines Corporation14$468
Astellas Pharma US Inc24$468
Puma Biotechnology, Inc.14$444
Genentech USA, Inc.16$420
Bayer17$399
Rigel Pharmaceuticals, Inc.12$344
Lilly USA, LLC20$339
Karyopharm Therapeutics Inc.10$317
Beone Medicines USA, Inc.13$303
Ipsen Biopharmaceuticals, Inc13$294
Array Biopharma Inc21$284
Boehringer Ingelheim11$278
Coherus Oncology, Inc.12$261
Genmab U.S., Inc.8$250
Dendreon Pharmaceuticals LLC8$233
Pharmacyclics LLC, An Abbvie Company11$231
AVEO Pharmaceuticals, Inc.10$213
Bristol Myers Squibb11$211
Stemline Therapeutics Inc.7$196
Servier Pharmaceuticals LLC8$192
Morphosys, US Inc.7$167
Deciphera Pharmaceuticals Inc.8$165
Galvanize Therapeutics, Inc1$158
Taiho Oncology, Inc.5$137
Pharmaessentia USA Corporation4$127
EMD Serono, Inc.5$106
Jazz Pharmaceuticals Inc.4$104
Tempus AI, Inc4$99
CSL Behring5$97
Alnylam Pharmaceuticals Inc.4$92
Immunocore Limited1$88
Agios Pharmaceuticals, Inc.4$85
Recordati_rare_diseases_inc.4$84
Iovance Biotherapeutics, Inc.3$83
Tersera Therapeutics LLC3$76
Dova Pharmaceuticals3$66
Foundation Medicine, Inc.3$62
Geron Corporation2$57
Immunogen, Inc.2$56
Progenics Pharmaceuticals, Inc.2$56
Legend Biotech USA Inc.2$55

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuroscience providers in Californiato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$11,110
Dexamethasone52$1,365
Potassium Chloride11$1,251
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$643
Hydroxyurea27$461
Ondansetron OdtOndansetron34$451
Triamcinolone Acetonide21$363
Promethazine Hcl18$211
Anastrozole11$203
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine20$175
Methylprednisolone17$153
Pantoprazole Sodium11$92
Prednisone17$90
Tramadol Hcl12$79
Levothyroxine Sodium17$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,270$11,11018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuroscience providers in Californiaon file to place this against a meaningful peer group, so we don't.

Other neuroscience in Rancho Mirage

Where these figures come from

Is this you, or does something look wrong? →